| 前收盘价格 | 8.21 |
| 成交量 | 6,361,552 |
| 预期市盈率 (P/E Forward) | 16.89 |
| 价格/销量 (P/S) | 32.22 |
| 股市价格/股市净资产 (P/B) | 61.05 |
| 52周波幅 |
| 营业利益率 (TTM) | -1,685.01% |
| 稀释每股收益 (EPS TTM) | -0.550 |
| 季度收入增长率 (YOY) | 25.90% |
| 总债务/股东权益 (D/E MRQ) | 35.04% |
| 流动比率 (MRQ) | 3.53 |
| 营业现金流 (OCF TTM) | -70.41 M |
| 杠杆自由现金流 (LFCF TTM) | -53.20 M |
| 资产报酬率 (ROA TTM) | -44.04% |
| 股东权益报酬率 (ROE TTM) | -278.55% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Precigen, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.83 |
|
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 10.56% |
| 机构持股比例 | 67.08% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Patient Capital Management, Llc | 30 Jun 2026 | 19,036,976 |
| Occam Crest Management Lp | 30 Jun 2026 | 3,605,941 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| THOMASIAN HARRY JR. | - | - | 0 | 0 |
| 累积净数量 | 0 | |||
| 累积净值 ($) | 0 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| THOMASIAN HARRY JR. | 职员 | 23 Sep 2026 | 执行期权 | 53,665 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合